Search clinical trials for: AML with Gene Mutations

Total 338155 results

Eilean Therapeutics

Not yet recruiting

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia

AML With Gene Mutations

Australia
Maximilian Stahl, MD
Syndax Pharmaceuticals

Not yet recruiting

Revumenib in Combination With 7+3 + Midostaurin in AML

Acute Myeloid Leukemia | Leukemia | AML | AML, Adult | AML With Gene Mutations

United States
Biomea Fusion Inc.

Recruiting

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Lymphoma | Lymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Cancer | Progression | Multiple Myeloma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Plasma Cell Myeloma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Refractory | Myeloma, Plasma-Cell | Myelomatosis | Acute Mixed-Phenotype...

United States, Spain, Netherlands, Greece, Italy
First Affiliated Hospital of Jinan University
Ruijin Hospital

Recruiting

Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations

Acute Myeloid Leukemia | Myelodysplastic Syndromes | P53 Mutation | Myeloid Malignancy | Temperature-Sensitive p53 Mutation | Sodium Stibogluconate

China
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance (AMELIORATE)

Acute Myeloid Leukemia With FLT3/ITD Mutation

Italy
Arog Pharmaceuticals, Inc.

Recruiting

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

United States, Germany, Spain, Italy, France, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Acute Myeloid Leukemia

United States, Canada, Puerto Rico, Australia
Novartis Pharmaceuticals

Active, not recruiting

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

Advanced Malignancies That Harbor IDHR132 Mutations

Belgium, Germany, Spain, Canada, Australia, United States, Netherlands, Singapore
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS) | Myeloproliferative Neoplasms (MPNs)

United States, Spain, Korea, Republic of, France, Taiwan, Australia, Belgium, Singapore, Israel, Canada, Germany, Finland
Novartis Pharmaceuticals

Completed

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

United States, Spain, Belgium, Germany, Japan, Taiwan, Turkey, Italy, Australia, Austria, Switzerland, Israel, Bulgaria, France, Norway, Brazil, Poland, Portugal, Czechia, Argentina
Stichting Hemato-Oncologie voor Volwassenen Nederland
Astellas Pharma Global Development, Inc.; Deutsch-Österreichische Studiengruppe...

Active, not recruiting

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Netherlands, Belgium, Germany, Switzerland, Australia, Finland, Norway, Sweden, Austria, France, Ireland, Lithuania, Luxembourg, Spain
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc

Completed

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

Acute Myeloid Leukemia | Leukemia | AML

United States
Astellas Pharma Global Development, Inc.

Approved for marketing

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

United States, Canada, Japan
Istituto Clinico Humanitas
Celgene

Unknown

Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia (Euro_IDH_AML)

Acute Myeloid Leukemia | IDH2 Gene Mutation | IDH1 Gene Mutation

Italy
Daiichi Sankyo, Inc.

Completed

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

Acute Myeloid Leukemia | Leukemia | AML | Myelodysplastic Syndrome | MDS

United States, Georgia
Daiichi Sankyo, Inc.

No longer available

Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

Acute Myeloid Leukemia With Gene Mutations
Spirita Oncology, LLC

Terminated

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

AML | MDS | CMML

United States
Astellas Pharma Global Development, Inc.

No longer available

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

Australia, Italy, United Kingdom
The University of New South Wales

Completed

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United Kingdom
Bristol-Myers Squibb

Not yet recruiting

Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Canada
Essen Biotech

Not yet recruiting

Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML (BAH244)

Acute Myeloid Leukemia | AML | AML, Adult | AML, Adult Recurrent

China
Sanofi

Recruiting

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Monotherapy Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (ESTUARY)

Dermatitis Atopic

United States
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

A Multicentre Prospective Cohort Study: Intensive Adjuvant Therapy for TNBC With BRCA Gene Mutation

Early-stage Triple-negative Breast Cancer With BRCA1/2 Mutations

China
Apollo Therapeutics Ltd

Not yet recruiting

A Study to Investigate APL-4098 Alone and/or in Combination With Azacitidine in R/R AML and High-Risk MDS

Myelodysplastic Syndrome With Excess Blasts | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Myelodysplastic Syndrome Acute Myeloid Leukemia
Sensorion

Not yet recruiting

A Phase I/II Clinical Trial With SENS-501 in Children Suffering From Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations (AUDIOGENE)

Otorhinolaryngologic Diseases | Ear Diseases | Hearing Disorders | Deafness | Hearing Loss, Sensorineural | Congenital Deafness | DFNB9 | OTOF Gene Mutation

France
National Cancer Center, China

Not yet recruiting

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations (EGFR)

NSCLC
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China
Huai'an First People's Hospital
Zhenjiang First People's Hospital; The Affiliated Hospital of Xuzhou Medical... and other collaborators

Recruiting

Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.

Acute Myeloid Leukemia

China
Children's Hospital of Soochow University

Recruiting

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

AML, Childhood | C-KIT Mutation | Refractory AML | Relapse/Recurrence | Core Binding Factor Acute Myeloid Leukemia

China
Remix Therapeutics

Recruiting

Study of REM-422 in Patients With AML or Higher Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Myeloid Leukemia Refractory | Higher Risk Myelodysplastic Syndromes

United States
ViGeneron GmbH

Recruiting

Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene

Retinitis Pigmentosa

Germany
The Second Affiliated Hospital of Kunming Medical...
Guizhou Provincial People's Hospital; Central South University; First Affiliated... and other collaborators

Not yet recruiting

Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult

Acute Myeloid Leukemia, Adult

China
Chang Gung University

Not yet recruiting

Music Therapy in Acute Leukemia Patients With Fatigue

Acute Myeloid Leukemia | Fatigue
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Effect of Mutations in T2DM Susceptibility Genes on the Expression of Susceptibility Genes in Patients With T2DM and Controls

Type 2 Diabetes Mellitus | Genetic Mutations | Gene Polymorphisms | Susceptibility, Genetic

China
National Cancer Institute (NCI)

Recruiting

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Breast Cancer | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Gastrointestinal Cancer | Genitourinary Cancer | Metastatic Solid Cancers

United States
Children's Oncology Group

Not yet recruiting

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Juvenile Myelomonocytic Leukemia
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (AQUA)

Dermatitis Atopic

Chile, United Kingdom, United States, Canada, Turkey, Israel, Korea, Republic of
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Solid Tumor | KRAS Mutation-Related Tumors

China
N.N. Petrov National Medical Research Center of...

Recruiting

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations (NТО-RAS)

Melanoma | Lung Cancer | Pancreas Cancer | Refractory Cancer | Colorectal Cancer Recurrent | RAS Mutation | Ras (Kras or Nras) Gene Mutation

Russian Federation
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids (SHORE)

Dermatitis Atopic

Japan, Chile, Canada, Argentina, United States, Turkey, China
Innostellar Biotherapeutics Co.,Ltd

Recruiting

Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Inherited Retinal Dystrophy

China
Manuel Coelho da Rocha

Not yet recruiting

Tailored vs. Empirical Helicobacter Pylori Infection Treatment

Helicobacter Pylori Infection

Portugal
Assiut University

Not yet recruiting

D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia

AML, Adult
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Non Small Cell Lung Cancer | ERBB2 Mutation-Related Tumors | Disitamab Vedotin | ERBB2 Gene Duplication
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

Dermatitis Atopic

Japan, China, Spain, United States, Argentina, United Kingdom, Denmark, Sweden, Turkey
Jazz Pharmaceuticals
Advice Pharma S.r.l.

Recruiting

VYxeoS Liposomal Italian Observational Study iN the Real Practice (VYSION)

Acute Myeloid Leukemia (AML) | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

Italy
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 1)

Dermatitis Atopic

Israel, Chile, Australia, United States, Canada, Korea, Republic of, Taiwan, China
Sanofi

Recruiting

Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis

Chile, Canada, Spain, United States, Australia, Portugal, Hungary, Italy
Aswan University

Recruiting

Blood Pressure Variability Effect on Right Ventricular Strain in Women With Hypertensive Disorders With Pregnancy

Preeclampsia | Hypertension, Pregnancy Induced

Egypt
National Cancer Institute (NCI)

Recruiting

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Inherited Bone Marrow Failure Syndrome | Familial Platelet Disorder With Predisposition to Myeloid Malignancies

United States

Search clinical trials for: AML with Gene Mutations

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations